As of November 6, 2026, Inhibrx Biosciences, Inc. is a publicly traded company (Nasdaq: INBX); its largest reported holder is Perceptive Advisors, with 9.99% on Schedule 13G/A of August 14, 2026, then Viking Global (9.3%) (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Inhibrx Biosciences, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Inhibrx Biosciences, Inc. a real, registered company?
- Inhibrx Biosciences, Inc. files with the SEC under CIK 2007919 (its SEC filings).
- Its shares are listed under the ticker INBX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in La Jolla, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Inhibrx Biosciences, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Schonfeld Strategic Advisors LLC (filed 2026-08-14).
Who are Inhibrx Biosciences, Inc.'s owners and officers?
Inhibrx Biosciences, Inc.: incorporated in Delaware; business address in La Jolla, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-10-28).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-28 | Bank Of America Corp /De/ | 2.4% |
| Schedule 13G, 2026-08-14 | Schonfeld Strategic Advisors LLC | 5.33% |
| Schedule 13G/A, 2026-08-14 | Perceptive Advisors LLC | 9.99% |
| Schedule 13G/A, 2026-08-14 | Viking Global Investors LP | 9.3% |
| Schedule 13G, 2026-08-03 | Bank Of America Corp /De/ | 5.9% |
| Schedule 13G/A, 2026-05-15 | Viking Global Investors LP | 9.99% |
| Schedule 13G/A, 2026-05-15 | Perceptive Advisors LLC | 9.99% |
| Schedule 13G/A, 2026-02-17 | Viking Global Investors LP | 9.99% |
| Schedule 13G, 2026-02-11 | Morgan Stanley | 7.9% |
| Schedule 13G, 2026-01-21 | Blackrock, Inc. | 5.3% |
| Schedule 13G/A, 2025-10-17 | Blackrock, Inc. | 4.7% |
Questions about who owns Inhibrx Biosciences, Inc.
Who owns Inhibrx Biosciences, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Inhibrx Biosciences, Inc.: Perceptive Advisors LLC (9.99%, Schedule 13G/A, filed 2026-08-14), Viking Global Investors LP (9.3%, Schedule 13G/A, filed 2026-08-14), Morgan Stanley (7.9%, Schedule 13G, filed 2026-02-11), Schonfeld Strategic Advisors LLC (5.33%, Schedule 13G, filed 2026-08-14) and Blackrock, Inc. (5.3%, Schedule 13G, filed 2026-01-21).
Who are the largest shareholders of Inhibrx Biosciences, Inc.?
By the share each holder's latest filing reports, the largest holders of Inhibrx Biosciences, Inc. on this page are Perceptive Advisors LLC (9.99%), Viking Global Investors LP (9.3%) and Morgan Stanley (7.9%).
When did Perceptive Advisors LLC buy into Inhibrx Biosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Perceptive Advisors LLC on this page is the Schedule 13G/A, filed 2026-05-15, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Inhibrx Biosciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Inhibrx Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Inhibrx Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Inhibrx Biosciences, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 1,074,046 shares (7.3% of shares outstanding), held indirectly through a jon f. kayyem and paige gates-kayyem family trust (Form 4, 2026-09-23).
- , the chief executive and a director: 970,453 shares (6.6% of shares outstanding), held indirectly through a lappe family trust (Form 4, 2026-10-14).
- , a director: 227,064 shares (1.5% of shares outstanding), held indirectly through a forsyth family trust dated july 20, 2001 (Form 4, 2026-09-08).
- Viking Global Opportunities Parent GP LLC, a 10% owner: 102,864 shares (0.70% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-10-09).
- , a 10% owner: 102,864 shares (0.70% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-10-09).
Shares outstanding: 14,717,660 as of 2026-08-07, from the company's latest SEC cover page.
How much has Inhibrx Biosciences, Inc. raised?
No fundraising or offering filing from Inhibrx Biosciences, Inc. is on file with us.
Keep reading
More on Inhibrx Biosciences, Inc. and the records around it.
Inhibrx Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Schonfeld Strategic Advisors LLC also filed stake reports on 5 other companies: Cardinal Infrastructure Group Inc. (May 2026), Jiuzi Holdings, Inc. (Feb 2026), Fate Therapeutics, Inc. (Aug 2025)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Nautilus Biotechnology, Inc. (Nov 2026), Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/inhibrx-biosciences